Abstract: The present invention discloses a surgical cement and a manufacturing method thereof. The surgical cement comprises a cementing component selected form the group of a basic calcium phosphate consisting of tetracalcium phosphate, alpha-tricalcium phosphate, decomposed hydroxyapatite, or a combination thereof; a setting reagent selected form the group of an acidic calcium citrate consisting of monocalcium citrate, dicalcium citrate, or a combination thereof; and water; wherein a weight ratio of the cementing component and the setting reagent ranges from about 1:1 to about 8:1. The surgical cement is bioresorbable and bioactive and is useful in orthopedic, maxillofacial and dental applications. In addition, the surgical cement of this invention has a good flow character and a relatively short setting time.

Abstract: This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof.

Abstract: Disclosed is an orally rapidly disintegrating tablet which has a good texture and taste in the oral cavity, such a sufficient hardness as not giving any worry of being chipped or dusted during production or transportation and good disintegrating properties in the oral cavity. The orally rapidly disintegrating tablet, which has a good texture and taste, an appropriate hardness, and good disintegrating properties, can be produced by using a composition, which is prepared by dispersing, by spray-drying, an inorganic excipient and starch(es) in complex particles composed of mannitol and xylitol, in an orally rapidly disintegrating tablet.

Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Abstract: There has been a need for an orally rapidly disintegrating tablet which has a good texture and taste in the oral cavity, such a sufficient hardness as not giving any worry of being chipped or dusted during production or transportation and good disintegrating properties in the oral cavity and can sustain a sufficient hardness even under humid conditions after opening. Disclosed are a disintegrating particle composition which is prepared by dispersing, in the presence of water, mannitol, xylitol, an inorganic excipient, a disintegrating agent and carmellose and drying, and an orally rapidly disintegrating tablet which comprises said disintegrating particle composition, an active substance and a disintegrating agent. The disintegrating tablet has a good texture and taste, an appropriate hardness and good disintegrating properties and can sustain a sufficient hardness under humid conditions.

Abstract: The present invention relates to a process for preparing a comestible product comprising xylitol said method comprising: (a) subjecting a composition comprising xylitol in an amount ranging from about 60% to about 100% by weight to extrusion treatment inside an extrusion apparatus under conditions sufficient to form and maintain the xylitol in a slurry and (b) then shaping the extruded slurry and cooling the product to form a solid. The present invention additionally is directed to a product produced therefrom.

Abstract: A method for treating gastric acid disorders with a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal; and a pharmaceutical composition of a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal are disclosed. A presently preferred proton pump inhibitor is lansoprazole, a presently preferred bicarbonate salt is sodium bicarbonate, and a presently preferred carbonate salt is sodium carbonate. The composition is a fast-acting formulation which reduces the undesirable belching associated with proton pump inhibitor formulations that contain high doses of sodium bicarbonate.

Abstract: A method of producing products includes diluting a mater in a quality water as a dilution water a plurality of times until solid stable water clusters are formed having a plurality of water molecules connected with one another by electrical dipole interaction via internal electric field of ions and having a permanent electric dipole moment with an electrical field surrounding the solid stable water clusters, and the produced solid stable water clusters can be used with an additional material to produce the final product.

Abstract: An inhaler includes a first body member and a second body member fit closely together to form an inhaler body, and an outlet. The first body member has a medicament chamber containing a unit dose of powdered medicament. A seal such as a foil strip seals the medicament chamber and extends outwardly of the inhaler body. In use, one end of the seal can be grasped by a user and withdrawn, fully or partially, from the inhaler body, to release the powdered medicament from the medicament chamber. The second body member includes a medicament collection well in which the medicament is collected upon its release from the medicament chamber. The medicament collection well forms part of an airway connecting into the outlet. In use, air can be drawn by inhalation at the outlet to entrain the powder medicament in the collection well for inhalation by a user.

Abstract: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer.

Abstract: The present invention provides an orally rapidly-disintegrating tablet comprising at least two particles. Regarding medicaments with unpleasant taste, the present invention provides a tablet comprising such medicament having a suitable hardness so that the tablet can be handled without any difficulty in the period from the formulation of the tablet to the administration thereof (in particular, a tablet which can maintain the hardness thereof when it is stored under a humidified condition); a small size; no unpleasant taste; a pleasant feeling in a mouth after administration; and an excellent disintegration character in the oral cavity and an excellent dissolution character in the gastrointestinal tract.

Abstract: The present disclosure relates to rheology modified, low foaming aqueous antimicrobial compositions. The compositions are phase stable under acidic conditions, and do not need to be rinsed from the surface to which they are applied. The present disclosure further relates to methods of use thereof.

Abstract: A method for preparing a composition of metal nanocrystals from at least one organometallic precursor in a solvent medium in the presence of a PEG ligand, including a carbon chain, at least one end of which is functionalized by a coordination grouping including at least one hetero atom, and having at least one [OCH2CH2]n grouping, n being an integer higher than 1, so as to be soluble both in the solvent medium and in water. The water-compatible and organic-compatible composition of metal nanocrystals thus obtained is also described.

Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.

Abstract: The present invention provides novel calcium phosphate nanoparticles suitable for efficient encapsulation of biologically active molecules. The invention further provides pharmaceutical compositions comprising these nanoparticles, as well as methods of making such nanoparticles and using them as carriers for therapeutic delivery of biologically active macromolecules.

Abstract: The invention relates to a liquid vehicle that can be used to create suspensions and/or solutions of liquid or powdered medications. The vehicle is thixotropic and has improved stability and rheologic characteristics. Vehicles of the invention include an aqueous medium and a suspending agent comprising a polysaccharide having at least 50% glucose repeating saccharide units and at least 90% alpha linkages. The polysaccharide can be a starch, modified starch, or glycogen. The aqueous medium and individual components of the vehicle provide a palatable and easily ingested drug preparation. The invention also provides a vehicle containing an aqueous medium, suspending agent comprising a polysaccharide having at least 50% glucose repeating saccharide units and at least 90% alpha linkages, buffer, and artificial sweetener, the combined suspending vehicle having a pH of about 3 to about 10 and an osmolality of 300 mOmsol or less.

Abstract: The present invention relates to a sodium chloride composition comprising an iron complex of tartaric acid wherein between 55 and 90% by weight of the tartaric acid is meso-tartaric acid. The present invention furthermore relates to a process to prepare such a sodium chloride composition and to the use of such a sodium chloride composition.

Abstract: The invention provides a biocompatible carrier and method for fabricating the same. The biocompatible carrier includes: a gel, and a plurality of metal nanoparticles, an organic compound or combinations thereof embedded in the gel, wherein the metal nanoparticles, the organic compound or combinations thereof are uniformly distributed in the gel.

Abstract: Method of making particle compositions exhibiting improved floodability and/or flowability properties. The compositions generally contain particles and non-surface modified nanoparticles.

Abstract: A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.

Abstract: The present invention relates to a Tabletting aid with a low water content and to a process for the preparation thereof. The Tabletting aid composition is a directly compressible composition, the use of which results in improved tablet properties.

Abstract: Disclosed are aerosol-mediated methods for synthesizing particles for biomedical and drug delivery applications. The method is based on the production of particles from sprayed polymeric micro or nano-droplets obtained by, for example, an air-jet nebulization process that is followed by gelation and/or hardening in a crosslinking fluid, non-solvent, precipitating solvent, or supercritical fluid.

Abstract: The present invention relates to a process for the preparation of a composition for the production of tablets and to a composition obtained thereby. This composition is a directly compressible composition which results both in improved tabletting properties and in improved tablet properties.

Abstract: The present invention provides a technique for prolonging the working time and setting time of a calcium sulfate hemihydrate paste by mixing calcium sulfate hemihydrate powder with an aqueous solution containing phosphate ions, so that the paste is suitable for operation and the resultant hardened calcium sulfate dihydrate block from the paste has an improved mechanical strength.

Abstract: The present invention provides a bone cement formula having a powder component and a setting liquid component, wherein the powder component includes a calcium sulfate source and a calcium phosphate source with a weight ratio of the calcium sulfate source less than 65%, based on the total weight of the calcium sulfate source and the calcium phosphate source, and the setting liquid component comprises ammonium ion (NH4+) in a concentration of about 0.5 M to 4 M, wherein the calcium phosphate source includes tetracalcium phosphate (TTCP) and dicalcium phosphate in a molar ratio of TTCP to dicalcium phosphate of about 0.5 to about 2.5, and the calcium sulfate source is calcium sulfate hemihydrate (CSH), calcium sulfate dehydrate (CSD), or anhydrous calcium sulfate.

Abstract: The invention relates to a curable dental retraction composition for reacting gingiva from a prepared tooth structure. The composition comprises an alginate, a di- and/or trivalent ion source, water, a retarder and a filler.

Abstract: The present invention relates to an ozone water that has the potential to find useful applications in a wide variety of technical fields and is capable of maintaining the effects of wiping out microorganisms such as bacteria, viruses and the like and inhibiting the growth thereof over long periods. The present invention provides ozone nano-bubbles capable of staying in a solution for an extended period of time and a method for producing the ozone nano-bubbles by instantaneously shrinking the diameters of ozone microbubbles contained in an aqueous solution by the application of a physical irritation to the ozone microbubbles in an aqueous solution.

Abstract: The invention is directed to a seed coating composition, to a seed coating cocktail, to a method for preparing a coated seed, to a coated seed, and to the use of specific inorganic particles. The seed coating composition for a seed comprises water and at least 35 wt. % by weight of the coating composition of inorganic particles, wherein the mean particle size (D50) of said inorganic particles as measured by laser obscuration time technology is 250 ?m or less.

Abstract: A light emitting composition including first color emitters and second color emitters. The first color emitters are configured to emit, upon exposure to an energy source, visible light at a target color in response to absorption of energy across a first band of wavelengths. The second color emitters are configured to emit, upon exposure to the energy source, visible light at the target color in response to absorption of energy across a second band of wavelengths. The light intensity observable at the target color is enhanced relative to reflected white light without emission from the first and second color emitters. The light emitting composition can be a part of a paint, an ink, a fabric, a thread, a road sign, a highway marking, an automobile, a boat, a plane, a reflector, a building product, a concrete product, an epoxy product, a jewelry product, colored contact lens, a candle product, a rubber product, a plastic product, or other colored surface.

Abstract: A lotion for opacifying a wet wipe. A wet wipe may comprise a lotion, the lotion comprising an opacifying agent. The lotion or the substrate may further comprise a retention aid. The substrate may comprise an opacifying agent the same as or different than the opacifying agent of the lotion. A method for opacifying a wet wipe by loading onto a wipe substrate a lotion comprising an opacifying agent. A method for aesthetically modifying a wet wipe by selectively loading onto a wipe substrate a lotion comprising an opacifying agent.

Abstract: A bone graft composition includes beta-tricalcium phosphate and calcium sulphate and slowly soluble sources of calcium ions and hydroxyl ions.

Abstract: The invention includes a microbe-mitigating architectural barrier that includes a barrier forming material, and at least one biocide. The barrier forming material may be a bitumen product, an elastomeric polymer and combinations thereof. The microbe-mitigating architectural barrier may be formed by applying an emulsion composition directly to an architectural surface, or it may be preformed and adhered or otherwise secured to the architectural surface in the form of a sheet or film. The invention also includes architectural assemblies and/or building envelopes that include the microbe-mitigating barrier. Related methods are encompassed within the scope of the invention.

Abstract: A method for producing a gel includes a liquid droplet ejection step in which a first liquid is ejected in the form of a droplet to a second liquid to allow the first liquid and the second liquid to react with each other, thereby producing a gel. The first liquid is a gel forming solution containing an alcohol-based solvent, wherein the alcohol-based solvent is contained therein in an amount of 4% or more by weight and less than 70% by weight of the total amount of the gel forming solution.

Abstract: Compositions and methods of using the compositions are provided for forming an embolus within a region of an anatomical lumen for a transitory period in order to achieve a therapeutic effect.

Abstract: Non-aqueous hydraulic cement compositions comprise a non-aqueous mixture of a powder composition and a non-aqueous water-miscible liquid. In one embodiment, powder composition is a Brushite or Monetite-forming calcium phosphate powder composition. In another embodiment, the powder composition comprises porous ?-tricalcium phosphate (?-TCP) granules and at least one additional calcium phosphate powder. In another embodiment, the powder composition comprises calcium silicate powder. In a further embodiment, the powder composition comprises calcium aluminate powder. In another embodiment, the powder composition is a cement composition and comprises nanopowders having a grain size of less than 1 micron. Hardened cements are formed from such hydraulic cement compositions, and methods of producing hardened cements, kits, and articles of manufacture employ such hydraulic cement compositions.

Abstract: A hydrogel composition is formed from a natural polymer derivative having a plurality of cross-linkable units depending therefrom, and a synthetic polymer derivative having a plurality of cross-linkable units depending therefrom, said natural and synthetic polymer derivatives having hydrolysable units disposed between the polymer backbone of said derivative and at least some of said cross-linkable units. The use of a combination of natural and synthetic polymers provides for biodegradability of the hydrogel, along with mechanical properties such as strength and elasticity.

Abstract: The present invention provides compositions and methods for detecting carboxymethyl-lysine (CML) and circulating receptor for advanced glycation end (RAGE) products, and methods for correlating CML and RAGE levels with age-related disease, hi particular, serum CML and/or circulating receptor for advanced glycation end (RAGE) products can be used as a clinical biomarker in diagnostics to identify people who are at a higher risk of developing adverse ageing-related outcomes.

Abstract: A multilayer effect pigment includes a transparent substrate, a layer of high refractive index material on the substrate, and alternating layers of low refractive index and high refractive index materials on the first layer, the total number of layers being an odd number of at least three, all adjacent layers differing in refractive index by at least about 0.2 and at least one of the layers having an optical thickness which is different from all of the other layers. The resulting multilayer effect pigment is not a quarter-wave stack. The present effect pigments may be used in cosmetic and industrial applications.

Abstract: The present invention provides: a carbon nanohorn composite including a carbon nanohorn, a substance encapsulated in the carbon nanohorn, and a polyamine adsorbed by chemical reaction firmly to a surface functional group present on the opening part on the surface of the carbon nanohorn, wherein the release amount and release rate of the encapsulated substance can be controlled using the difference in size, substituent or three-dimensional structure of the polyamine, which is used as a plug; a method of controlling the release of the encapsulated substance; and a process for producing the carbon nanohorn composite. The release amount and release rate of the substance encapsulated in the carbon nanohorn composite is controlled by selecting a polyamine molecule, which plugs the opening part formed in the carbon nanohorn by oxidation, by its size, substituent or three-dimensional structure.

Abstract: The present invention describes a balanced aqueous electrolyte solution. In particular, a balanced aqueous electrolyte solution that is particularly suitable as a solution for intravenous and subcutaneous infusion because of its being plasma-adapted is described. In addition to the balanced electrolyte solution itself, an electrolyte mixture as well as a process for preparing the balanced electrolyte solution from this mixture, and a medicament comprising the solution and optionally an active ingredient are provided.

Abstract: An angle-dependent interference pigment based on transparent or translucent inorganic flake serving as a substrate is provided. The substrate is coated by coatings (A)+(B)+(C) and optionally coating (D), so as to form a “high-low-high” refractive index layered structure. The coatings (A) and (C) consist of metal oxides, silicate, aluminates and/or a mixture thereof. The coating (B) consist of silicon oxide, hydrous silicon oxide, aluminum oxide, hydrous aluminum oxide, magnesium oxide, hydrous magnesium oxide and/or a mixture thereof. The angle-dependent interference pigments have high color saturation in the transitional region and a significantly gradual color change in the color changing region. The present pigments can be used as colored coatings, including printing ink, or can be used in the preparation of plastics, glass, ceramics and the like. The pigment of the present invention is particularly used in the cosmetic industry which has a very high requirement on gradual color change.

Abstract: Disclosed are compositions useful in a wide variety of applications, including heat transfer fluids which possess a highly desirable and unexpectedly superior combination of properties, and heat transfer systems and methods based on these fluids. The preferred heat transfer fluid comprises from about 1 to about 40 percent, on a weight basis, of carbon dioxide (CO2) and from about 99 to about 60 percent, on a weight basis, of a compound having the Formula I XCFzR3-z (I), where X is a C2 or a C3 unsaturated, substituted or unsubstituted, alkyl radical, each R is independently Cl, F, Br, I or H, and z is 1 to 3. A preferred compound of Formula I is tetrafluoropropene, particularly 1,1,1,3-tetrafluoropropene and/or 1,1,1,3-tetrafluoropropene.

Abstract: Compositions, systems and methods utilizing engineered surgical irrigants providing delivery of components with therapeutic or other secondary benefits. Engineered irrigants provide targeted delivery of desired agents, including agents for propulsion of nano-devices, agents including molecular probes, gene expression agents, magnetically orientable agents, agents for discrete tissue temperature detection and tissue regeneration agents.

Abstract: The present invention relates to an oral dispersible tablet comprising at least one filler selected from sugars and sugar alcohols, and microcrystalline cellulose.

Abstract: The present invention discloses an activated biocidal aqueous solution containing hydrogen peroxide (activated peroxide solution) obtainable by subjecting an initial solution of hydrogen peroxide in water to a non-thermal electrical discharge process, such as a glow discharge plasma or a corona discharge. The resulting activated peroxide solution containing 0.05 to 20% (w/w) hydrogen peroxide has a pH in the range of 2 to 4, an oxidation-reduction potential (ORP) in the range of 400 to 600 mV, and the solution when having a peroxide content in the range of 0.05% to 0.5% (w/w) has a conductivity in the range of 100 to 500 ?Siemens/cm, the solution when having a peroxide content in the range of 0.1% to 5% (w/w) has a conductivity in the range of 100 to 450 ?Siemens/cm, and the solution when having a peroxide content in the range of 5% to 20% (w/w) has a conductivity in the range of 100 to 350 ?Siemens/cm.

Abstract: An ultrasonic mixing system having a treatment chamber in which at least two separate phases can be mixed to prepare an emulsion is disclosed. Specifically, at least one phase is a dispersed phase and one phase in a continuous phase. The treatment chamber has an elongate housing through which the phases flow longitudinally from a first inlet port and a second inlet port, respectively, to an outlet port thereof. An elongate ultrasonic waveguide assembly extends within the housing and is operable at a predetermined ultrasonic frequency to ultrasonically energize the phases within the housing. An elongate ultrasonic horn of the waveguide assembly is disposed at least in part intermediate the inlet and outlet ports, and has a plurality of discrete agitating members in contact with and extending transversely outward from the horn intermediate the inlet and outlet ports in longitudinally spaced relationship with each other.

Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.

Abstract: Provided is an instrument for alleviating addictive drug craving which can be safely administered to an addictive drug-dependent patient by a definite method in practice without causing any undesirable effects on therapy and terminate a series of behaviors through the administration so as to achieve an excellent effect on the therapy for alleviating addictive drug craving. An instrument for alleviating addictive drug craving (11) which comprises a pseudo injection agent (31) enclosed in a pseudo container (21). To the outer face of the pseudo container (21), which is an ampule-shaped container being similar in appearance and structure to a container of an addictive drug (X), a pseudo injection agent label (41), which is almost the same in constitution to a product label of the container of the addictive drug (X) except having the term “PSEUDO” added hereto, is attached.

Abstract: The present invention relates to mixed crystals comprising a) leavening agent and b) 0.1 to 5000 ppm by weight of crystallization aid, based on the total amount of the leavening agent, in the form of at least polymer, wherein when hydrophilic cellulose derivatives are used as crystallization aid, the amount thereof is reduced to less than 100 ppm by weight, based on the total amount of the leavening agent. The present invention further relates to the production of the mixed crystals and to the use thereof in the production of bakery products, as acid regulator in foods, in the production of cosmetics products, in the synthesis and formulation of pharmaceutical products, and also as blowing agent in industrial processes such as, for example, the production of foam rubber, or for fire-extinguishing formulations. The present invention relates, furthermore, to the production of bakery products.

Abstract: A composition for stabilizing chlorine dioxide maintains a chlorine dioxide concentration nearly constant in the agent containing chlorine dioxide dissolved therein even when chlorine dioxide is continuously released as gas from agent, and includes a chlorite and a pH adjuster. The pH adjuster is an acid or a salt thereof having a buffering property whose pH is 2.5 to 6.8 as a 5% aqueous solution at 25° C.